Analysts at Chardan Capital started coverage on shares of Vicore Pharma (NASDAQ:VCRE – Get Free Report) in a research note issued on Wednesday, Benzinga reports. The firm set a “buy” rating and a $15.00 price target on the stock. Chardan Capital‘s target price suggests a potential upside of 58.90% from the stock’s current price.
A number of other research firms have also recently weighed in on VCRE. Wall Street Zen raised Vicore Pharma to a “hold” rating in a research report on Saturday, October 24th. Weiss Ratings began coverage on shares of Vicore Pharma in a research note on Thursday, October 8th. They set a “sell (e-)” rating on the stock. Finally, Jefferies Financial Group initiated coverage on shares of Vicore Pharma in a report on Friday, October 9th. They set a “buy” rating and a $25.00 price target on the stock. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $20.00.
Read Our Latest Stock Report on VCRE
Vicore Pharma Stock Performance
NASDAQ VCRE traded up $0.28 during trading hours on Wednesday, hitting $9.44. 25,161 shares of the company’s stock traded hands, compared to its average volume of 26,943. Vicore Pharma has a 52 week low of $7.88 and a 52 week high of $17.80.
Vicore Pharma (NASDAQ:VCRE – Get Free Report) last released its quarterly earnings results on Friday, August 21st. The company reported ($0.05) earnings per share for the quarter. The business had revenue of $0.23 million for the quarter.
Vicore Pharma Company Profile
Vicore Pharma is a Swedish clinical-stage biopharmaceutical company focused on developing treatments for severe respiratory diseases, particularly pulmonary fibrosis and other conditions involving lung injury and impaired tissue repair. The company is headquartered in Gothenburg, Sweden, and conducts research and clinical development activities aimed at addressing significant unmet medical needs.
Vicore’s lead drug candidate is buloxibutid, also known as C21, an oral small-molecule agonist of the angiotensin II type 2 receptor.
See Also
- Five stocks we like better than Vicore Pharma
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Vicore Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vicore Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
